Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome.
Wang H, Tian S, Zhao Q, Blumenschein W, Yearley JH, Secreto CR, Sinha S, Call TG, Wang Y, Parikh SA, Kenderian SS, He R, Leis JF, Shi M, Van Dyke DL, Kay NE, Slager SL, Braggio E, Yan H, Ding W. Wang H, et al. Among authors: secreto cr. Hematol Oncol. 2022 Apr;40(2):302-306. doi: 10.1002/hon.2950. Epub 2021 Dec 3. Hematol Oncol. 2022. PMID: 34806797 No abstract available.
Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.
Zent CS, Secreto CR, LaPlant BR, Bone ND, Call TG, Shanafelt TD, Jelinek DF, Tschumper RC, Kay NE. Zent CS, et al. Among authors: secreto cr. Leuk Res. 2008 Dec;32(12):1849-56. doi: 10.1016/j.leukres.2008.05.014. Epub 2008 Jun 27. Leuk Res. 2008. PMID: 18584865 Free PMC article. Clinical Trial.
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N, Jelinek DF, Tschumper RC, Secreto CR, Lin TS, Grever MR, Shanafelt TD, Zent CS, Call TG, Heerema NA, Lozanski G, Byrd JC, Lucas DM. Awan FT, et al. Among authors: secreto cr. Blood. 2009 Jan 15;113(3):535-7. doi: 10.1182/blood-2008-08-173450. Epub 2008 Nov 13. Blood. 2009. PMID: 19008456 Free PMC article. Clinical Trial.
Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.
Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE. Shanafelt TD, et al. Among authors: secreto cr. J Clin Oncol. 2009 Aug 10;27(23):3808-14. doi: 10.1200/JCO.2008.21.1284. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470922 Free PMC article. Clinical Trial.
Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression.
Ding W, Nowakowski GS, Knox TR, Boysen JC, Maas ML, Schwager SM, Wu W, Wellik LE, Dietz AB, Ghosh AK, Secreto CR, Medina KL, Shanafelt TD, Zent CS, Call TG, Kay NE. Ding W, et al. Among authors: secreto cr. Br J Haematol. 2009 Nov;147(4):471-83. doi: 10.1111/j.1365-2141.2009.07868.x. Epub 2009 Sep 8. Br J Haematol. 2009. PMID: 19751240 Free PMC article.
27 results